FDA official logo
GSRS logoPFDA official logo

NUZEFATIDE PEVEDOTIN

UNII:CIT3DOS0DW
Type:INGREDIENT SUBSTANCE
Formula:C201H315N53O52S3
Preferred Substance Name:NUZEFATIDE PEVEDOTIN
InChIKey:
YZUGAHYDHBVJAU-LOXUOWRQSA-N
GSRS Full Record:
CIT3DOS0DW
i

  • 2648849-70-9
  • (3S)-4-[[(9R,13R,15S,18S,21S,24S,30S,33S,36R,39S,42S,48S,51R,54S,57S,60R)-24-(2-amino-2-oxoethyl)-57-(4-carbamimidamidobutyl)-60-carbamoyl-51-(carboxymethyl)-13-hydroxy-42-(1H-imidazol-5-ylmethyl)-54-(1H-indol-3-ylmethyl)-18,33,39-tris(2-methylpropyl)-4,10,16,19,22,25,31,34,37,40,43,49,52,55,58,65,68-heptadecaoxo-21-propan-2-yl-7,62,71-trithia-1,3,11,17,20,23,26,32,35,38,41,44,50,53,56,59,66-heptadecazahexacyclo[34.31.5.13,66.011,15.026,30.044,48]triheptacontan-9-yl]amino]-3-[[(2S)-6-carbamimidamido-2-[[(2S)-2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[3-[[5-[[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylcarbamoyl]oxymethyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoyl]amino]propanoyl-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
  • BT-5528
  • BT5528
  • L-Cysteinamide, N-(4-carboxy-1-oxobutyl)-β-alanyl-N-methylglycyl-N-methylglycyl-N-methylglycyl-N-methylglycyl-N-methylglycyl-N-methylglycyl-N-methylglycyl-N-methylglycyl-N-methylglycyl-N-methylglycyl-L-alanyl-N6-(aminoiminomethyl)-L-lysyl-L-α-aspartyl-S-[3-oxo-3-[tetrahydro-3,5-bis(3-mercapto-1-oxopropyl)-1,3,5-triazin-1(2H)-yl]propyl]-L-cysteinyl-(4R)-4-hydroxy-L-prolyl-L-leucyl-L-valyl-L-asparaginyl-L-prolyl-L-leucyl-L-cysteinyl-L-leucyl-L-histidyl-L-prolyl-D-α-aspartyl-L-tryptophyl-N6-(aminoiminomethyl)-L-lysyl-, cyclic (15→22),(15→29)-bis(thioether), (1→1′)-amide with N-methyl-N-[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
  • NUZEFATIDE PEVEDOTIN [USAN]
  • Nuzefatide Pevedotin
  • S<sup>3.15</sup>,S<sup>3.22</sup>,S<sup>3.29</sup>-[(1,3,5-triazinane-1,3,5-triyl)tris(3-oxopropane-3,1-diyl)]{N-[5-oxo-5-({L-valyl-N<sup>5</sup>-carbamoyl-L-ornithyl[(4-aminophenyl)methoxy]carbonyl-N-methyl-L-valyl-Lvalyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(2R,3R)-N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanamide}-N2.1-yl)pentanoyl]-β-alanyldecakis(N-methylglycyl)-L-alanyl-N6-carbamimidoyl-L-lysyl-L-α-aspartyl-L-cysteinyl-(4R)-4-hydroxy-L-prolyl-L-leucyl-L-valyl-L-asparaginyl-L-prolyl-L-leucyl-L-cysteinyl-L-leucyl-L-histidyl-L-prolyl-D-α-aspartyl-L-tryptophyl-N6-carbamimidoyl-L-lysyl-Lcysteinamide}
  • nuzefatide pevedotin [INN]




UNII - CIT3DOS0DW | UNII Search Service